NEW YORK--(BUSINESS WIRE)--CB Insights today named Abridge, the leader in medical conversation AI, to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022.
"From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”
“More and more, providers are finding themselves under pressure from strained healthcare systems, somehow needing to see more patients while also improving patient experiences and outcomes,” said Dr. Shivdev Rao, co-founder and CEO of Abridge. “That changes with Abridge. We’re incredibly proud that CB Insights has recognized the progress we’ve made in leveraging cutting-edge generative AI that can scale to this clinician burnout crisis and improve the care delivery experience for both providers and their patients.”
Utilizing the CB Insights platform, the research team selected these 150 winners from a pool of over 13,000 private companies, including applicants and nominees. They were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed over 3,000 Analyst Briefings submitted by applicants.
Abridge uses cutting-edge NLP and generative AI to bring context and understanding to every medical conversation. Abridge helps health systems and telemedicine providers structure and summarize conversations into automated documentation in real-time and at scale, making it easier to reduce provider burnout while also increasing patient satisfaction and outcomes. Armed with a proprietary dataset derived from more than 1.5 million medical encounters and more peer-reviewed papers about medical conversation AI than any other entity, Abridge has already helped more than 2,000 providers practice at the top of their license and 200,000 patients stay on top of their health.
Quick facts on the 2022 Digital Health 150:
- Equity funding and deals: Since 2017, this year's Digital Health 150 winners have raised around $5.6B in equity funding across 378 deals. This includes approximately $1.6B raised across 85 deals in 2022 YTD alone.
- Unicorns: This year's list includes only 5 unicorns with a $1B+ valuation, around 3% of the total list. For comparison, last year's list contained 17. This tracks with a broader drop in new unicorns across sectors in 2022
- Global Reach: Winners in this year's Digital Health 150 span 18 countries across 5 continents. A quarter (25%) are headquartered outside of the US — the most in the history of our list. While the US still leads, the UK comes in second with 9 winners, followed by Canada with 5 and Brazil with 3.
About CB Insights
CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
Abridge structures and summarizes information from the most important signals in healthcare — spoken conversations. Abridge’s ambient and generative AI technology is powered by industry-leading R&D, as evidenced by their depth of peer-reviewed publications and user experience design. The company’s solutions help clinicians practice at the top of their license and patients stay on top of their health. Whether an appointment takes place in-person or via telemedicine, Abridge captures and documents the conversation to meet the needs of providers, patients, and enterprises. Visit http://www.abridge.com and @AbridgeHQ to get the latest information.